These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22697130)

  • 21. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.
    Ambrose CS; Anderson EJ; Simões EA; Wu X; Elhefni H; Park CL; Sifakis F; Groothuis JR
    Pediatr Infect Dis J; 2014 Jun; 33(6):576-82. PubMed ID: 24622396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations.
    Bennett MV; McLaurin K; Ambrose C; Lee HC
    PLoS One; 2018; 13(10):e0205399. PubMed ID: 30379957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nirsevimab and Hospitalization for RSV Bronchiolitis.
    Assad Z; Romain AS; Aupiais C; Shum M; Schrimpf C; Lorrot M; Corvol H; Prevost B; Ferrandiz C; Giolito A; Valtuille Z; Bendavid M; Cohen JF; Toubiana J; de Pontual L; Delande CF; Levy M; See P; Cohen R; Levy C; Angoulvant F; Lenglart L; Gits-Muselli M; Biran V; Diallo K; Alemede O; El Hebil MM; Durrmeyer X; Labouret G; Casanovas N; Hallak B; Maréchal O; Jung C; Bréhin C; Ouldali N
    N Engl J Med; 2024 Jul; 391(2):144-154. PubMed ID: 38986058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Respiratory syncytial virus acute respiratory infection-associated hospitalizations in preterm Mexican infants: A cohort study.
    Benítez-Guerra D; Piña-Flores C; Zamora-López M; Escalante-Padrón F; Lima-Rogel V; González-Ortiz AM; Guevara-Tovar M; Bernal-Silva S; Benito-Cruz B; Castillo-Martínez F; Martínez-Rodríguez LE; Ramírez-Ojeda V; Tello-Martínez N; Lomelí-Valdez R; Salto-Quintana J; Cadena-Mota S; Noyola DE
    Influenza Other Respir Viruses; 2020 Mar; 14(2):182-188. PubMed ID: 31917902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.
    Winterstein AG; Knox CA; Kubilis P; Hampp C
    JAMA Pediatr; 2013 Dec; 167(12):1118-24. PubMed ID: 24126903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prospective regional study of an epidemic of respiratory syncytial virus (RSV) bronchiolitis].
    Grimaldi M; Cornet B; Milou C; Gouyon JB
    Arch Pediatr; 2002 Jun; 9(6):572-80. PubMed ID: 12108310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
    Rodriguez WJ; Gruber WC; Welliver RC; Groothuis JR; Simoes EA; Meissner HC; Hemming VG; Hall CB; Lepow ML; Rosas AJ; Robertsen C; Kramer AA
    Pediatrics; 1997 Mar; 99(3):454-61. PubMed ID: 9041304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Respiratory syncytial virus bronchiolitis: severe respiratory forms in hospitalized infants].
    Gold F
    Arch Pediatr; 2006 Dec; 13 Suppl 5():S8-11. PubMed ID: 17550820
    [No Abstract]   [Full Text] [Related]  

  • 31. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.
    Stockman LJ; Curns AT; Anderson LJ; Fischer-Langley G
    Pediatr Infect Dis J; 2012 Jan; 31(1):5-9. PubMed ID: 21817948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases.
    Shmueli E; Goldberg O; Mei-Zahav M; Stafler P; Bar-On O; Levine H; Steuer G; Mussaffi H; Gendler Y; Blau H; Prais D
    Pediatr Pulmonol; 2021 Jul; 56(7):2204-2211. PubMed ID: 33913611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
    Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
    Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
    Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review.
    Ralston S; Hill V
    J Pediatr; 2009 Nov; 155(5):728-33. PubMed ID: 19647839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age.
    Doering G; Gusenleitner W; Belohradsky BH; Burdach S; Resch B; Liese JG
    Pediatr Infect Dis J; 2006 Dec; 25(12):1188-90. PubMed ID: 17133170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost.
    Atkins JT; Karimi P; Morris BH; McDavid G; Shim S
    Pediatr Infect Dis J; 2000 Feb; 19(2):138-43. PubMed ID: 10694001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.
    Figueras-Aloy J; Carbonell-Estrany X; Quero J;
    Pediatr Infect Dis J; 2004 Sep; 23(9):815-20. PubMed ID: 15361718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased risk of wheeze and decreased lung function after respiratory syncytial virus infection.
    Zomer-Kooijker K; van der Ent CK; Ermers MJ; Uiterwaal CS; Rovers MM; Bont LJ;
    PLoS One; 2014; 9(1):e87162. PubMed ID: 24498037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.